BioProtocol unveils OpenLabs platform at DeSci Berlin to merge AI with decentralized research funding

Scientific research funding has a well-known bottleneck problem. Getting a grant through traditional channels can take months, sometimes years, of paperwork, peer review, and institutional gatekeeping. Bio Protocol thinks it has a faster lane.

At DeSci.Berlin 2026 on June 19, the project launched OpenLabs, a platform designed to let researchers turn raw scientific ideas into funded projects using a combination of AI collaboration and community voting. The conference, held at KÖNIG GALERIE as part of Berlin Blockchain Week, has become a recurring launchpad for decentralized science initiatives, with past events spawning projects like Molecule Labs.

What OpenLabs actually does

The platform integrates funding mechanisms directly into its collaborative environment. Researchers can develop projects, coordinate with community members, and secure funding all within a single interface. No bouncing between grant portals, DAO voting dashboards, and separate collaboration tools.

The system pairs human researchers with AI-driven workflows for project development. Community members vote on which projects deserve funding, creating a decentralized alternative to the traditional grant committee model. The BIO token serves as the governance and utility token powering these decisions within Bio Protocol’s broader ecosystem.

Two flagship projects were highlighted at launch. RheumaAI is an AI agent focused on rheumatology research. PeptAI targets peptide discovery.

Bio Protocol’s bigger picture

OpenLabs doesn’t exist in a vacuum. Bio Protocol has positioned itself as financial infrastructure for biotech innovation, using tokenized intellectual property and governance mechanisms called BioDAOs to channel capital toward scientific research.

The project has raised over $33M through its BIO Genesis initiative. The DeSci movement applies blockchain principles to scientific research, including transparent funding trails, community governance over research priorities, and tokenized ownership of intellectual property.

What this means for investors

The BIO token hasn’t shown dramatic price movement in the immediate aftermath of the announcement. For BIO token holders, the governance utility becomes more meaningful as OpenLabs scales, with voting on which scientific projects receive funding representing a more concrete use case than many governance tokens can claim.

The $33M already raised through BIO Genesis gives Bio Protocol runway to iterate on OpenLabs without immediately needing to demonstrate revenue.

The risk that rarely gets discussed in DeSci circles is regulatory. Tokenized intellectual property in biotech sits at an uncomfortable intersection of securities law, patent law, and pharmaceutical regulation. As these projects mature from concept to actual drug discovery pipelines, the legal complexity will only increase.

Disclosure: This article was edited by Editorial Team. For more information on how we create and review content, see our Editorial Policy.